Featured Research

from universities, journals, and other organizations

Joint implants without an expiry date

Date:
June 2, 2014
Source:
Empa Swiss Federal Laboratories for Materials Science and Technology
Summary:
Artificial joints have a limited lifespan. After a few years, many hip and knee joints have to be replaced. Much more complex are intervertebral disc implants, which cannot easily be replaced after their "expiry date" and which up to now have had to be reinforced in most cases. This restricts the patient's freedom of movement considerably. Researchers have now succeeded in coating mobile intervertebral disc implants so that they show no wear and will now last for a lifetime.

Due to the daily stresses and movement in the body, even the best artificial joints wear out; the material undergoes wear, and wear particles can trigger unwanted immune reactions, making it necessary to replace the joint. This is normally a standard procedure that can be repeated up to three times with most implants. As bone material is lost each time an implant is explanted, the new joint has to replace more bone and is therefore larger. In the case of intervertebral discs, this is virtually impossible. They are too close to spinal nerves and tissue structures that could be damaged by another operation.

Up to now, intervertebral discs have not been replaced by mobile joints, but by so-called cages, a kind of place holder that both supports and allows the adjacent vertebrae to grow and fuse together. However, this causes stiffening at the point where previously the disc had provided adequate freedom of movement. Over the years, this stiffening can result in the adjacent discs also having to be reinforced due to the increased stress on them. Mobile intervertebral disc implants could reduce this problem. However, many products currently available carry the risk of triggering allergies or rejection reactions due to material abrasion.

What makes artificial joints durable?

Initial attempts to increase the lifespan of artificial joints were made by various manufacturers in the past using a super-hard coating made of DLC ("diamond-like carbon") -- with disastrous consequences. Approximately 80% of DLC-coated hip joints failed within just eight years. Researchers at Empa's "Laboratory for Nanoscale Materials Science" investigated this problem and found that the implant failure did not originate from the coating itself, but was caused by the corrosion behaviour of the bonding agent between the DLC layer and the metal body. This layer was made of silicon which corroded over the years, causing it to flake, which led to increased abrasion and, as a result, bone loss. "Our aim was to find a bonding agent which does not corrode and which lasts a lifetime in the body," explains Kerstin Thorwarth.

The first step towards intervertebral discs This was a laborious task, as the Empa researcher emphasises: "We tried half the periodic table." One was finally found and tantalum was used as the bonding agent. This coating was tested in a so-called total disc replacement -- a mobile disc implant. We simulated 100 million cycles, i.e. about 100 years of movement in a specially designed joint simulator. The small intervertebral disc implant held out, remaining fully operational with no abrasion or corrosion. The new bonding agent is soon also to be used in combination with DLC coatings for other joints. "The intervertebral disc is the most awkward joint in terms of implants. Because tantalum has performed so well, the DLC project can now be applied to other joints," says Thorwarth.


Story Source:

The above story is based on materials provided by Empa Swiss Federal Laboratories for Materials Science and Technology. Note: Materials may be edited for content and length.


Cite This Page:

Empa Swiss Federal Laboratories for Materials Science and Technology. "Joint implants without an expiry date." ScienceDaily. ScienceDaily, 2 June 2014. <www.sciencedaily.com/releases/2014/06/140602095123.htm>.
Empa Swiss Federal Laboratories for Materials Science and Technology. (2014, June 2). Joint implants without an expiry date. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/06/140602095123.htm
Empa Swiss Federal Laboratories for Materials Science and Technology. "Joint implants without an expiry date." ScienceDaily. www.sciencedaily.com/releases/2014/06/140602095123.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins